Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
- Webcast to be held Thursday, October 6, 2016 at 11:00 a.m. ET
STAMFORD, Conn., Oct. 03, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and Chief Executive Officer, will participate in a webcast featuring innovations in pain management therapies. The webcast is part of a series from Biopharma Dealmakers, a quarterly supplement in Nature Biotechnology and Nature Reviews Drug Discovery.
Four companies that are working to address unmet needs in pain management will present their developments, which include analgesics with novel mechanisms of action, medical devices, and opioids with reduced potential for abuse and physical dependence. The webcast will also include a roundtable discussion and a question and answer session with Dr. Chalmers and the other speakers.
Details for the webcast are as follows:
Date: Thursday, October 6, 2016
Time: 11:00 a.m. ET
Moderator: Raveena Bhambra, Editor of BioPharma Dealmakers
Participants:
- Dr. Derek Chalmers, President and CEO of Cara Therapeutics
- Dr. Jeffrey Herz, President and CEO of Algomedix, Inc.
- Dr. Jessica Preciado, Director of Product Development and Principal Scientist of Myoscience
- Dr. Steve Doberstein, Senior Vice President and Chief Scientific Officer of Nektar Therapeutics
For more information, and to register for this free webcast, visit: http://www.workcast.com/register?cpak=5922214840089056&referrer=SPONSOR_CaraTherapeutics.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Jesse Baumgartner Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
